|Day Low/High||49.99 / 50.85|
|52 Wk Low/High||42.48 / 63.69|
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
* Ignore slowing global economic growth at your own risk * Global debt will continue to serve as a governor to growth * Global debt has not been supported by growth in the global economy * Like the Potemkin Village, global debt growth has created an...
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
These stocks and sectors are safe havens, and may even be opportunities.
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
Here's the only way to explain why stocks jump like mad if the companies underneath them only perform slightly better than the analysts worried they would.
Equities are a bit higher across the board since our last update. Homebuilders continue to be in the green as 30-year mortgage rates hover near three-year lows. This is starting to have an effect as purchase application demand has posted its biggest...
And as the semiconductor sector continues to shine, Brooks Automation is a name to keep in mind.
Breaking down the impact on Facebook, Alphabet and Amazon of congressional hearings.
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
Watch the Russell 2000, housing activity, and mergers and acquisitions.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Let's check out the charts of BMY.
The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.
Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
What happened to the business president? I think what happened is that the polls are showing that whatever the president is doing is working.
BMY is not 'out of the woods' yet, but aggressive traders could probe the long side here.
This is the first time I can ever recall when a president is so attuned to the market that he will bend to its wishes.
As usual, the stocks that bounce back first are the tech stocks with little Chinese exposure and the consumer packaged goods that just demonstrated good numbers.